 |
 |
 |
|
|
 |
EXECUTIVE
MANAGEMENT TEAM
|
 |
Bruce
L.A. Carter, Ph.D.
Chairman of the Board and Chief Executive Officer
Dr. Carter was appointed Chairman of the
Board in April 2005.
Dr.
Carter has been ZymoGenetics' Chief
Executive Officer since April 1998. Dr.
Carter first joined ZymoGenetics in 1986
as Vice President of Research and Development.
In 1994, he was chosen as Corporate Executive
Vice President and Chief Scientific Officer
for Novo Nordisk A/S, the former parent
company of ZymoGenetics. He was elected
to the board of ZymoGenetics in 1987 and
was appointed president of the company in 1998. Dr.
Carter led the negotiations that established
ZymoGenetics as an independent company
from Novo Nordisk in 2000. Dr. Carter
held various positions of increasing responsibility
at G.D. Searle & Co., Ltd. from 1982
to 1986 and was a Lecturer at Trinity
College, University of Dublin from 1975
to 1982. Dr. Carter received a B.Sc. with
Honors in Botany from the University of
Nottingham, England, and a Ph.D. in Microbiology
from Queen Elizabeth College, University
of London. |
 |
Michael J. Dwyer
Senior Vice President, Sales and
Marketing
Mike Dwyer joined ZymoGenetics in May 2006
as Senior Vice President of Marketing and
Sales. Mr. Dwyer has nearly thirty years
experience in biologic and pharmaceutical
marketing and sales. He is responsible for
ZymoGenetics’ sales, marketing and
operations/logistics team. Prior to ZymoGenetics,
Mr. Dwyer served as Vice President, Diabetes
Sales for Novo Nordisk, where he was responsible
for planning and implementing selling strategies,
designing launch strategies and operations
and recruiting sales forces for the U.S.
launch of NovoSeven® and Norditropin®.
Mr. Dwyer has held positions in marketing
and sales at Bayer/Miles Inc. where he assisted
in developing the introductory strategy
and product launch for Kogenate® (recombinant
Factor VIII). Mr. Dwyer also served as Vice
President of Marketing and Materials Management
for Caremark Therapeutic Services, a biopharmaceutical
provider of home therapies and services.
Mr. Dwyer holds an M.B.A. from Pepperdine
University and a B.S. from University of
Dayton.
|
 |
Heather L. Franklin
Senior Vice President, Business Development
Heather L. Franklin was named Senior Vice President, Business Development in June, 2008. Prior to that, she was Vice President, Business Development from January 2005 to June 2008, Senior Director, Strategic Alliance Management from July 2003 to January 2005 and Director, Strategic Alliance Management from January 2002 to July 2003. In these roles she was instrumental in negotiating and managing major partnerships with Novo Nordisk, Merck Serono and Bayer. Ms. Franklin joined ZymoGenetics in January, 2001 as Director, Research Project Management to establish a research project management system after holding roles of increasing responsibility in clinical and research project management at Amgen and Targeted Genetics from 1994 to 2001. She started her career in research roles at Seattle Biomedical Research Institute and Targeted Genetics. Ms. Franklin received a B.S. from the University of North Carolina, Chapel Hill, M.S. from the University of Washington and an M.B.A from the Wharton School of the University of Pennsylvania.
|
 |
Darren R. Hamby
Senior Vice President, Human Resources
Darren Hamby was appointed Senior Vice President, Human Resources in July 2007. Previously, Mr. Hamby served as Vice President, Human Resources from August 2004 to June 2007, Senior Director, Human Resources from September 2002 to July 2004, and Director, Human Resources from July 2000 to August 2002. Mr. Hamby joined ZymoGenetics in September 1997 to manage compensation and employee benefit programs. From 1987 to 1997, Mr. Hamby held human resources positions of increasing responsibility with the Federal Home Loan Bank of Seattle. Mr. Hamby earned a Bachelor of Business Administration degree, with an emphasis in human resources management, and an M.B.A. from Pacific Lutheran University.
|
 |
Vaughn B. Himes, Ph.D.
Senior Vice President, Technical Operations
Dr. Himes was appointed Senior Vice President, Technical Operations in May 2006. Dr. Himes joined ZymoGenetics in November 2005 as Vice President, Commercial Manufacturing Operations. Previously, Dr. Himes served as Vice President for Worldwide Manufacturing Operations for Corixa Corporation with responsibility for manufacturing operations, process development and quality control in support of commercial and clinical supplies. From 2000 to 2003, Dr. Himes served as Vice President, Manufacturing Operations for Targeted Genetics Corporation, where he was responsible for manufacturing and clinical supply operations for gene delivery products. From 1999 to 2000, Dr. Himes served as Vice President Product Development for Genovo, Inc. Prior to that, Dr. Himes held positions of increasing responsibility over ten years with Wyeth-Lederle Vaccines, including Associate Director of Biological Development, Manager of Viral Vaccine Development and Clinical Production, and Cell Culture Pilot Plant Supervisor. Dr. Himes received a Bachelors of Arts in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota. |
 |
James A. Johnson
Executive Vice President, Chief Financial Officer
and Treasurer
Mr. Johnson joined ZymoGenetics in February
2001 as Senior Vice President, Chief Financial
Officer and Treasurer, bringing over 20
years of financial experience to the company.
Prior to joining ZymoGenetics, he held numerous
positions at Targeted Genetics Corporation,
most recently as Senior Vice President and
Chief Financial Officer, where he led private
and public offerings, as well as establishing
a joint venture program to advance the company's
technology platforms. Other previous positions
include Vice President of Finance at Immunex
Corporation, Vice President and Controller
at Safeco Properties, Inc., and Senior Auditor
at Arthur Young. Mr. Johnson received a
B.A. in Business Administration from the
University of Washington. |
| |
|
 |
Nicole Onetto, M.D.
Senior Vice President and Chief
Medical Officer
Dr. Nicole Onetto joined ZymoGenetics as
Senior Vice President and Chief Medical
Officer in September 2005. Dr. Onetto has
over fifteen years of clinical drug development
experience at leading biotechnology and
pharmaceutical companies. Previously, Dr.
Onetto was Executive Vice President and
Chief Medical Officer at OSI Pharmaceuticals,
where she headed the Development Organization and led
the registration program for Tarceva (TM).
Prior to that, Dr. Onetto served as Senior
Vice President of Medical Affairs at Gilead
Sciences and was also Senior Executive
at Bristol-Myers Squibb in the oncology
organization. While at BMS, she was
the International Project Leader for
Taxol. She also held clinical research positions
of increasing responsibility at NeXstar
Pharmaceuticals, Immunex and Hoechst. Dr.
Onetto holds a Bachelor of Arts from
the Academy of Paris (France), a Masters
of Science in Pharmacology from the
University of Montreal (Canada), a Doctor
of Medicine degree from the University
of Paris (France) and is qualified in pediatrics
and hematology/oncology. |
 |
Suzanne
M. Shema, J.D.
Senior Vice President and General Counsel
Law
and Compliance
Ms. Shema has served as our Senior Vice
President, Law and Compliance since April
2003. Previously, Ms. Shema served as
Vice President, Intellectual Property
and Legal Affairs from December 2001 to
April 2003 and Senior Director, Intellectual
Property from May 2001 to December 2001.
From February 2000 to May 2001, Ms. Shema
served as General Counsel at aQuantive,
Inc., an internet advertising company.
From July 1998 to February 2000, Ms. Shema
served as corporate counsel at ZymoGenetics.
From 1991 to March 1998, she served as
Associate General Counsel at Research
Corporation Technologies, Inc., a technology
management company. From 1989 to 1991,
Ms. Shema served as Associate General
Counsel at NeoRx Corporation, a biotechnology
company. From 1985 to 1988, she served
as an associate at the law firm of Seed
and Berry. Ms. Shema received a B.S. in
Chemistry from the University of Texas,
an M.S. in Chemistry from the University
of Washington and a J.D. from the University
of Washington School of Law. |
 |
Douglas E. Williams, Ph.D.
President and Chief Scientific
Officer
Dr. Williams was named President of the company in July 2007. He joined ZymoGenetics in 2004
as Chief Scientific Officer and Executive
Vice President and is responsible for the
company's research and development programs.
Dr. Williams has held senior level positions
at a number of notable biotechnology companies,
including Seattle Genetics, Immunex, Amgen
and Genesis Research and Development, a
New Zealand based biotechnology company.
As Executive Vice President and Chief Technology
Officer at Immunex, Dr. Williams played
a significant role in the discovery and
early development of Enbrel, the first biologic
approved for the treatment of rheumatoid
arthritis. In addition, Dr. Williams was
a member of Immunex Corporation's Board
of Directors. Before entering the biotechnology
industry, Dr. Williams served on the faculty
of the Indiana University School of Medicine
and worked in the Department of Laboratory
Medicine at the Roswell Park Memorial Institute.
Dr. Williams earned a B.S. magna cum laude
in Biological Sciences from the University
of Massachusetts, Lowell and a Ph.D. in
Physiology from the State University of
New York at Buffalo. |
Corporate
Governance
|
|
|
|
Back to top
